tiprankstipranks

Samuel Saks Insider Profile

4 Followers
Samuel Saks, CDO, Director at Auspex Pharma, holds 14.00K shares in Protagonist Therapeutics (Ticker: PTGX), holds 214.19K shares in PDL BioPharma (Ticker: PDLI), holds 6.61K shares in Tonix Pharma (Ticker: TNXP).
tipranks
Samuel Saks

Samuel Saks
Auspex Pharma (ASPX)
CDO, Director

Ranked #35,845 out of 98,743 Corporate Insiders

Profitable Transactions

33%
1 out of 3 Profitable Transactions

Average Return

+9.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$40M
99.07%
0.92%
<0.01%
<0.01%
A breakdown of Samuel Saks's holdings

Insider Roles

Jazz Pharmaceuticals
(JAZZ)
CEO, Director
Protagonist Therapeutics
(PTGX)
CMO
Assertio Therapeutics
(ASRT)
Director
Tonix Pharma
(TNXP)
Director
Roles that Samuel Saks holds in companies

Most Profitable Insider Trade

Stock:
Auspex Pharma
(ASPX)
Rating:Informative Buy
Date:Feb 12, 2014 - Feb 12, 2015
Return:+183.70%
The most profitable trade made by Samuel Saks

Samuel Saks's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
ASPX
Auspex Pharma
May 05, 2015
Uninformative Sell
Protagonist Therapeutics
Feb 26, 2021
CMO
Uninformative Buy
$364.84K
Tonix Pharma
Jun 21, 2016
Director
Informative Buy
50.00K
$1.28K
PDLI
PDL BioPharma
Jun 12, 2018
Uninformative Buy
150.00K
$529.05K
Assertio Therapeutics
May 13, 2016
Director
Uninformative Sell
12.86K
$3.53K
Jazz Pharmaceuticals
CEO, Director
$39.42M
List of latest transactions for each holding click on a transaction to see Samuel Saks's performance on stock

Samuel Saks insider profile FAQ

What is the percentage of profitable transactions made by Samuel Saks?
The percentage of profitable transactions made by Samuel Saks is 33%.
    What is the average return per transaction made by Samuel Saks?
    The average return per transaction made by Samuel Saks is 9.30%.
      What stocks does Samuel Saks hold?
      Samuel Saks holds: ASPX, PTGX, TNXP, PDLI, ASRT, JAZZ stocks.
        What was Samuel Saks’s latest transaction?
        Samuel Saks latest transaction was an Uninformative Buy of ―.
          What was Samuel Saks's most profitable transaction?
          Samuel Saks’s most profitable transaction was an Informative Buy of ASPX stock on February 12, 2014. The return on the trade was 183.70%.
            What is Samuel Saks's role in Auspex Pharma?
            Samuel Saks's role in Auspex Pharma is CDO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.